(Updated - September 23, 2026 6:24 AM EDT)

Guggenheim analyst Debjit Chattopadhyay upgraded Editas Medicine (NASDAQ: EDIT) from Neutral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE